Nov 21, 2023, 14:18
5 new drug indications by FDA Oncology in the last 10 days – Oncology Brothers
Quoting Oncology Brothers on X/Twitter:
“What just happened?
5 new drug indications by FDA Oncology in the last 10 days. As Community Oncologists, we need to know them all:
1. Fruquintinib in refractory mCRC, mPFS 3.7mos vs 1.8mos.
2. Pembrolizumab (+Chemo) in 1L mGEJ/Gastric Ca, mOS 12.9mos Vs 11.5mos.
3. Capivasertib (+Fulvestrant) in PIK3CA/AKT1/PTEN +ve metastatic HR+ Breast Ca after >1 endocrine Rx, mPFS 7.2mos Vs 3.6mos.
4. Repotrectinib in 1L mNSCLC ROS1 +ve, ORR 79% and mDoR 34mos.
5. Enzalutamide (+/- ADT) in non-Mets HSPC, 5 year MFS: 87.3% (combo) Vs 80% (Enza monotherapy) Vs 71.4% (ADT alone).”
Source: Oncology Brothers/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 14:40
Nov 14, 2024, 14:39
Nov 14, 2024, 14:28
Nov 14, 2024, 14:05
Nov 14, 2024, 13:49